CY1112039T1 - Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης - Google Patents

Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Info

Publication number
CY1112039T1
CY1112039T1 CY20111101053T CY111101053T CY1112039T1 CY 1112039 T1 CY1112039 T1 CY 1112039T1 CY 20111101053 T CY20111101053 T CY 20111101053T CY 111101053 T CY111101053 T CY 111101053T CY 1112039 T1 CY1112039 T1 CY 1112039T1
Authority
CY
Cyprus
Prior art keywords
holoperidon
isomeri
variable
optical
fouoro
Prior art date
Application number
CY20111101053T
Other languages
Greek (el)
English (en)
Inventor
Dominique Grimler
Hans O Kalkman
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1112039T1 publication Critical patent/CY1112039T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CY20111101053T 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης CY1112039T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
EP02767454A EP1425272B1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
CY1112039T1 true CY1112039T1 (el) 2015-11-04

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111101053T CY1112039T1 (el) 2001-08-31 2011-11-02 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100058T CY1113550T1 (el) 2001-08-31 2013-01-23 Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK2305656T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
RU2309154C9 (ru) 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
WO2006039663A2 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008121899A2 (en) 2007-03-29 2008-10-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2008144599A2 (en) 2007-05-18 2008-11-27 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
CA2698534C (en) 2007-09-10 2018-10-09 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
EP2222301B1 (en) * 2007-12-13 2014-10-08 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
US9072742B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
US9074256B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
WO2010117931A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of treatment based on polymorphisms of the kcnq1 gene
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
CA2865845C (en) * 2012-03-14 2020-02-18 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
ES2870498T3 (es) 2015-02-17 2021-10-27 Vanda Pharmaceuticals Inc Iloperidona para el tratamiento de esquizofrenia
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
IL285721B2 (en) * 2019-02-21 2025-03-01 Obi Pharma Inc Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
EP4507698A1 (en) 2022-04-13 2025-02-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
AU2023408198A1 (en) 2022-12-19 2025-05-29 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
IL324466A (en) 2023-06-02 2026-01-01 Vanda Pharmaceuticals Inc Method of treatment with iloperidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
DE69021645T2 (de) * 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2149742T1 (es) * 1997-07-03 2000-11-16 Asahi Chemical Ind Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Also Published As

Publication number Publication date
US20090176739A1 (en) 2009-07-09
EP2305656B1 (en) 2012-10-24
CY1113550T1 (el) 2016-06-22
DK2305656T3 (da) 2013-02-11
US20130296366A1 (en) 2013-11-07
ES2398434T3 (es) 2013-03-19
JP2010100633A (ja) 2010-05-06
JP2013116905A (ja) 2013-06-13
US20110201646A1 (en) 2011-08-18
DK1425272T3 (da) 2011-11-21
HK1156309A1 (en) 2012-09-07
HK1066536A1 (en) 2005-03-24
PT1425272E (pt) 2011-10-19
ATE518845T1 (de) 2011-08-15
ES2398434T8 (es) 2017-10-09
JP2015227368A (ja) 2015-12-17
EP1425272A1 (en) 2004-06-09
EP1425272B1 (en) 2011-08-03
PT2305656E (pt) 2013-01-10
ES2370634T3 (es) 2011-12-21
US8314129B2 (en) 2012-11-20
JP2005504783A (ja) 2005-02-17
WO2003020707A1 (en) 2003-03-13
JP2015214577A (ja) 2015-12-03
EP2305656A1 (en) 2011-04-06
JP2013227335A (ja) 2013-11-07
US20050020632A1 (en) 2005-01-27
US7977356B2 (en) 2011-07-12

Similar Documents

Publication Publication Date Title
CY1113550T1 (el) Οπτικα ισομερη ενος μεταβολιτη ιλοπεριδονης
NO20051965L (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
DE60233043D1 (de) 2-iminoimidazolderivate
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
DK1379520T3 (da) N-substituerede ikke-aryl-heterocykliske NMDA/NR2B-antagonister
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
DE502004009532D1 (de) Fungizide ternäre wirkstoffkombinationen
NO20045002L (no) (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister
HRP20080446T3 (en) Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
DE602004016850D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE498600T1 (de) Inden derivate als pharmazeutika
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
ATE360612T1 (de) In 4-stellung substituierte piperidinderivate
NO20072587L (no) Fenyldiazepankarboksamider og anilerte fenylpiperazinkarboksamider inneholdende oksygen og benyttet som dopamin D3 antagonister
EA200401290A1 (ru) НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
ATE322479T1 (de) Benzamidinderivate
HRP20030653B1 (en) Novel benzoylguanidine salt
PT1384476E (pt) Derivados azolilcarbinol de arilo (ou heteroarilo) para o tratamento de doencas respiratorias
WO2001040220A3 (de) 3-(4,5-dihydroisoxazol-3-yl)-substituierte benzoylpyrazole als herbizide
ATE389326T1 (de) 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazo e und ihre verwendung als herbizide
DE602005005638D1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
DE50014393D1 (de) Cyclopropyl-anellierte 3-(4,5-dihydroisoxazol-3-yl)-substituierte benzoylpyrazole als herbizide